GW Pharma (GWPH) PT Raised to $200 at Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
GW Pharma (GWPH) PT Raised to $227 at Stifel
May 7, 2019 8:37 AM EDTStifel analyst Paul Matteis raised the price target on GW Pharma (NASDAQ: GWPH) to $227.00 (from $191.00) while maintaining a Buy rating after spending time with management post 1Q print. The company reaffirmed views that the Epidiolex launch to date, considering all of the... More
GW Pharma (GWPH) PT Raised to $229 at Cantor Fitzgerald
May 7, 2019 6:42 AM EDTCantor Fitzgerald analyst Elemer Piros raised the price target on GW Pharma (NASDAQ: GWPH) to $229.00 (from $196.00) while maintaining a Overweight rating following Q1 results.
Piros commented, "The company reported the first full quarter of EPIDIOLEX revenues of $33.5 million. Additionally, GWPH reported positive... More
GW Pharma (GWPH) PT Raised to $218 at BofA/Merrill Lynch
May 7, 2019 6:25 AM EDTBofA/Merrill Lynch analyst Tazeen Ahmad raised the price target on GW Pharma (NASDAQ: GWPH) to $218.00 (from $200.00) while maintaining a Buy rating.
... MoreOppenheimer Upgrades GW Pharma (GWPH) to Outperform
May 7, 2019 6:13 AM EDTOppenheimer analyst Esther Rajavelu upgraded GW Pharma (NASDAQ: GWPH) from Perform to Outperform with a price target of $162.00 (from $234.00).
The analyst comments "GWPH reported strong Epidiolex uptake, driven by new patients, bolus 4Q patients, and conversion of most EAP/OLE patients to... More
GW Pharma (GWPH) Reports Positive Phase 3 Pivotal Trial Results for EPIDIOLEX Oral Solution in Patients with Seizures Associated With TSC
May 6, 2019 5:42 PM EDTGW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced positive top-line results of a randomized, double-blind, placebo-controlled Phase 3 clinical trial of EPIDIOLEX® (cannabidiol or CBD) CV in the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare and severe form of childhood-onset epilepsy. In this trial, EPIDIOLEX met its primary endpoint, which was the reduction in seizure frequency compared to baseline of the Epidiolex 25 mg/kg/day dose group vs placebo (p=0.0009).... More
